GlassScriptPhysician profile
John Shenouda
NPI 1952660532
$3,423.91
in general payments reported to CMS, 2019-2025
22 companies · $1,279 in 2025
The $1,279 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $18.53 · 2021: $425 · 2022: $896 · 2023: $61.48 · 2024: $462 · 2025: $1,279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,170 · Travel and Lodging: $632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,170.32 |
| Travel and Lodging | $632.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $883.99 | 2022-2025 | Jetstream Sc, General - Angiography |
| Edwards Lifesciences Corporation | $590.60 | 2022-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Medtronic, INC. | $538.94 | 2021-2025 | Ffrangio, Reveal Linq |
| Abbott Laboratories | $167.45 | 2019-2025 | Aveir |
| Medtronic Vascular, INC. | $146.58 | 2019 | |
| Pfizer INC. | $126.79 | 2019-2025 | |
| Abiomed | $126.66 | 2024-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $120.57 | 2024-2025 | |
| Heartflow, INC. | $113.55 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $112.66 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $98.33 | 2021-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.26 | 2023-2025 | Jardiance |
| Amgen INC. | $62.80 | 2024-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $61.26 | 2024-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $32.96 | 2020-2023 | Xarelto |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $30.43 | 2025 | |
| Esperion Therapeutics, INC. | $30.40 | 2024 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $30.07 | 2024-2025 | Camzyos |
| Kiniksa Pharmaceuticals International, Plc | $17.00 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $16.46 | 2025 | Evkeeza |
| Kiniksa Pharmaceuticals, LTD. | $15.64 | 2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $14.51 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Shenouda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.